Celgene

Views & Analysis

ASCO 2018 Preview – what to expect from this year’s conferen...

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.

News

Evotec and Celgene unite to drive forward oncology R&D

Evotec and Celgene have joined forces in a long-term strategic drug discovery and development partnership, to identify new therapeutics in oncology.

News

Ozanimod launch delayed by failures in FDA application

The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).

Oncology

Celgene's COO quits after troubles with new drugs

Celgene’s chief operating officer and inflammatory diseases guru Scott Smith has quit the company, in the aftermath of the FDA’s rejection of a key multiple sclerosis pill, and a late-stage

News